Drawing for FLORA

USPTO serial 99786906

FLORA

Reviewed by CopyMark Law Group

Status 641Office Action
Filing date
Status date
Registration date
—
Examiner
BURCH, JILLIAN RENEE
Law office
TMO LAW OFFICE 122

What this means

The USPTO has issued an Office Action on this application. A response is typically required before the deadline, or the application can be abandoned.

Status 641: Status 641 means the USPTO mailed a non-final Office Action identifying issues with your application. You typically have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.

Need help with FLORA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Office Action, set up monitoring, or talk with CopyMark.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Jonathan Hood

Jonathan Hood HOOD VENTURE COUNSEL, P.C.75 South BroadwaySuite 4484White Plains, NY 10601

Goods and services

ClassDescriptionStatusFirst use
035Advertising and marketing services in the field of healthcare and pharmaceuticals; business consulting services in the field of pharmaceutical marketing and healthcare communications; data analytics services for healthcare professionals and pharmaceutical companies; placement of advertising messages in electronic health record systems; strategic business consulting services in the field of pharmaceutical media and healthcare communications; market research services in the field of healthcare and pharmaceuticalsACTIVEJan 21, 2024
038Electronic transmission of targeted advertising and marketing communications to healthcare professionals and patients; providing online platforms for the delivery of healthcare messaging at the point of care; electronic delivery of pharmaceutical marketing content via digital networksACTIVEJan 21, 2024
042Software as a service (SaaS) featuring software for healthcare marketing, pharmaceutical advertising, and point-of-care communications; providing real-time data technology solutions for pharmaceutical marketing and physician profiling; development and provision of proprietary technology platforms for healthcare communications; data management services in the field of healthcare and pharmaceutical marketingACTIVEJan 21, 2024

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 20, 2026XELGAPPLICATION EXTENSION GRANTED/RECEIPT PROVIDED—
Oct 20, 2026XELRAPPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED—
Jul 23, 2026GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 23, 2026GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 23, 2026CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 22, 2026DOCKASSIGNED TO EXAMINER—
Apr 25, 2026MAFRAPPLICATION FILING RECEIPT MAILED—
Apr 25, 2026NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Apr 25, 2026NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance